Parthanatos

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

Retrieved on: 
Tuesday, May 19, 2020
Medicine, Clinical medicine, Antineoplastic drugs, PARP inhibitor, Health, Treatment of cancer, Oncology, Chemotherapy, Cancer, Poly (ADP-ribose) polymerase, Parthanatos

We are delighted to be able to present at this prestigious oncology-focused meeting this new study on the effect of AsiDNA on these persistent cells when combined with PARP inhibitors.

Key Points: 
  • We are delighted to be able to present at this prestigious oncology-focused meeting this new study on the effect of AsiDNA on these persistent cells when combined with PARP inhibitors.
  • These data clearly reinforce AsiDNA's interest in the fight against resistance, which is the main challenge in cancer treatment today.
  • Translational research has highlighted the distinctive properties of AsiDNA, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status.
  • AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.

Analysis on Impact of COVID19-PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024 | Expanded Application of PARP Inhibitors to Boost Growth | Technavio

Retrieved on: 
Tuesday, May 19, 2020
Health, Pharmaceutical, Branches of biology, Programmed cell death, Biology, DNA repair, Poly (ADP-ribose) polymerase, PARP, Poly(ADP-ribose) glycohydrolase, PARP inhibitors, Lactams, Parthanatos, ADP-ribosylation

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43323

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43323
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our PARP (poly ADP-ribose polymerase) inhibitors market report covers the following areas:
    This study identifies extensive ongoing research as one of the prime reasons driving the PARP inhibitors market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the PARP inhibitors market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, RTT, Programmed cell death, Biology, PARP inhibitor, Poly (ADP-ribose) polymerase, Gynaecology, PARG, Medicine, Ovarian cancer, Cancer, Parthanatos

al., published a paper in Cancer Cell, entitled "DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors," which provides a potentially differentiated and complementary treatment approach to PARP inhibitors.

Key Points: 
  • al., published a paper in Cancer Cell, entitled "DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors," which provides a potentially differentiated and complementary treatment approach to PARP inhibitors.
  • The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.
  • Dr. Caroline Springer, Ph.D., Director, Drug Discovery Unit, Cancer Research UK Manchester Institute, the principal investigator at the Cancer Research UK Manchester Institute, will lead the in vivo studies.
  • "We are excited to expand our partnership with IDEAYA to evaluate key biological hypotheses based on DNA replication vulnerabilities to predict sensitivity of PARG inhibitors in ovarian cancer.

Growth of PARP (Poly ADP-ribose Polymerase) Inhibitors Market to be Impacted by Expanded Application of PARP Inhibitors | Technavio

Retrieved on: 
Friday, October 18, 2019
Pharmaceutical, Health, Oncology, Branches of biology, Enzymes, Biology, Programmed cell death, PARP, Nucleotides, Poly (ADP-ribose) polymerase, PARP inhibitors, Adenosine diphosphate ribose, Poly(ADP-ribose) glycohydrolase, Olaparib, Parthanatos

PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Geographic landscape
    PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Indication
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • PARP inhibitors are known for their high efficacy in the treatment of diseases such as solid tumors.
  • Vendors save on R&D costs by incorporating single molecule of these inhibitors for conducting multiple pre-clinical and clinical trial studies.
  • The vast application landscape of PARP inhibitors encourages vendors to carry out research activities for new cancer indications.

Global Synthetic Lethality-based Drugs and Targets Market Report 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways - ResearchAndMarkets.com

Retrieved on: 
Monday, September 30, 2019
Health, Pharmaceutical, Branches of biology, Biology, Programmed cell death, Cellular processes, Poly (ADP-ribose) polymerase, Synthetic lethality, PARP inhibitor, PARP, DNA repair, Olaparib, Parthanatos

The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.
  • The Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways' report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics.
  • Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality.
  • Further, several such drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications.